Targeting adenovirus with use of constrained peptide motifs

Details Targeting adenovirus with use of constrained peptide motifs Targeting adenovirus with use of constrained peptide motifs

1998-08-06

2000-05-02

Guzo, David

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

435 691, 4353201, 536 2372, 536 234, C12N 510, C12N 1586

Patent

active

060571551

ABSTRACT:
The present invention provides a chimeric adenovirus fiber protein, which differs from the wild-type coat protein by the introduction of a nonnative amino acid sequence in a conformationally-restrained manner. Such a chimeric adenovirus fiber protein according to the invention is able to direct entry into cells of a vector comprising the chimeric fiber protein that is more efficient than entry into cells of a vector that is identical except for comprising a wild-type adenovirus fiber protein rather than the chimeric adenovirus fiber protein. The nonnative amino acid sequences encodes a peptide motif that comprises an epitope for an antibody, or a ligand for a cell surface receptor, that can be employed in cell targeting. The present invention also pertains to vectors comprising such a chimeric adenovirus fiber protein, and to methods of using such vectors.

REFERENCES:
patent: 4487829 (1984-12-01), Sharp et al.
patent: 4517686 (1985-05-01), Ruoslahti et al.
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4593002 (1986-06-01), Dulbecco
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4797368 (1989-01-01), Carter et al.
patent: 4956281 (1990-09-01), Wallner
patent: 5024939 (1991-06-01), Gorman
patent: 5096815 (1992-03-01), Wu et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5198346 (1993-03-01), Lardner et al.
patent: 5204445 (1993-04-01), Plow et al.
patent: 5223394 (1993-06-01), Wallner
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5246921 (1993-09-01), Reddy et al.
patent: 5332567 (1994-07-01), Goldenberg
patent: 5349053 (1994-09-01), Landolfi
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5443953 (1995-08-01), Hansen et al.
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5534423 (1996-07-01), Palsson
patent: 5543328 (1996-08-01), McClelland et al.
patent: 5547932 (1996-08-01), Curiel et al.
patent: 5552311 (1996-09-01), Sorscher et al.
patent: 5559099 (1996-09-01), Wickham et al.
patent: 5571698 (1996-11-01), Lardner et al.
patent: 5622699 (1997-04-01), Ruoshlahti et al.
patent: 5661133 (1997-08-01), Leiden et al.
patent: 5672344 (1997-09-01), Kelley et al.
patent: 5674722 (1997-10-01), Mulligan et al.
patent: 5693509 (1997-12-01), Cotton et al.
patent: 5695991 (1997-12-01), Lindholm et al.
patent: 5712136 (1998-01-01), Wickham et al.
patent: 5731190 (1998-03-01), Wickham et al.
patent: 5756086 (1998-05-01), McClelland et al.
patent: 5770442 (1998-06-01), Wickham et al.
Athapilly et al., J. Mol. Biol., 242, 430-455 (1994).
Kinloch et al., J. Biol. Chem., 259, 6431-6436 (1984).
Roberts et al., Science, 232, 1148-1151 (1986).
Toogood et al., J. Gen. Virol., 73, 1429-1435 (1992).
Albiges-Rizo et al., Journal of Biological Chemistry, 266 (6), 3961-3967 (1991).
Aumailley et al., FEBS, 291, 50-54 (1991).
Bai et al., Journal of Virology, 67 (9), 5198-5205 (1993).
Ball-Goodrich et al., Virology, 184, 175-186 (1991).
Batra et al., Gene Therapy, 1, 255-260 (1994).
Barinaga, Science, 266, 1326 (1994).
Boursnell et al., Gene, 13, 311-317 (1981).
Caillet-Boudin et al., J. Mol. Biol., 217, 477-486 (1991).
Chroboczek et al., Virology, 186, 280-285 (1992).
Chu et al., Gene Therapy, 1, 292-299 (1994).
Cotten et al., Proc. Natl. Acad. Sci. USA, 87, 4033-4037 (1990).
Cotten et al., Proc. Natl. Acad. Sci. USA, 89, 6094-6098 (1992).
Crawford-Miksza et al., Journal of Virology, 70 (3), 1836-1844 (1996).
Crompton et al., J. Gen. Virol., 75 (1), 133-139 (1994).
Crystal, Science, 270, 404-410 (1995).
Curiel et al., Human Gene Therapy, 3, 147-154 (1992).
Curiel et al., Proc. Natl. Acad. Sci. USA, 88, 8850-8854 (1991).
Defer et al., Journal of Virology, 64 (8), 3661-3673 (1990).
Dupuit et al., Human Gene Therapy, 6, 1185-1193 (1995).
Etienne-Julan et al., Journal of General Virology, 73, 3251-3255 (1992).
Falck-Pedersen, Abstract of National Institutes of Health Grant Application No. 1 PO1 HL51746-01UB: 0004 entitled "Gene Therapy For Cystic Fibrosis" (1994).
Falgout et al., Journal of Virology, 62 (2), 622-625 (1988).
Gall et al., Journal of Virology, 70, 2116-2123 (1996).
Greber et al., Cell, 75, 477-486 (1993).
Green et al., EMBO Journal, 2 (8), 1357-1365 (1983).
Grubb et al., Nature, 371, 802-806 (1994).
Han et al., Proc. Natl. Acad. Sci. USA, 92, 9747-9751 (1995).
Henry et al., Journal of Virology, 68 (8), 5239-5246 (1994).
Hong et al., Virology, 185 (2), 758-767 (1991).
Horvath et al., Journal of Virology, 62 (1), 341-345 (1988).
Huang et al., Journal of Virology, 69 (4), 2257-2263 (1995).
Jolly, Cancer Gene Therapy, 1 (1), 51-64 (1994).
Karayan et al., Virology, 202, 782-785 (1994).
Kass-Eisler et al., Proc. Natl Acad. Sci. USA, 90, 11498-11502 (1993).
Koivunen et al., Bio/Technology, 13, 265-269 (1995).
Komoriya et al., Journal of Biological Chemistry, 266 (23), 15075-15079 (1991).
Maraveyas et al., Acta Oncologica, 32 (7/8), 741-746 (1993).
Marshall, Science, 269, 1050-1055 (1995).
Massia et al., J. Biolog. Chem., 11, 8053-8059 (1993).
Mastrangeli et al., Human Gene Therapy, 7, 79-87 (1996).
Mastrangeli et al., Ped. Pulm., Suppl., 12, 230, Abst. No. 180 (1995).
Mathias et al., Journal of Virology, 68 (10), 6811-6814 (1994).
Michael et al., Gene Therapy, 2, 660-668 (1995).
Michael et al., Journal of Biological Chemistry, 268 (10), 686-6869 (1993).
Miller et al., FASEB Journal, 9, 190-199 (1995).
Neda et al., Journal of Biological Chemistry, 266 (22), 14143-14146 (1991).
Nemerow et al., Biology of Vitronectins and Their Receptors (Preissner et al., eds), 177-184 (Elsevier Science Publishers, 1993).
Nemerow et al., Trends in Cell Biology, 4, 52-55 (1994).
Novelli et al., Virology, 185, 365-376 (1991).
Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, (1995).
Peteranderl et al., Biochemistry, 31, 12272-12276 (1992).
Russell et al., Nucleic Acids Research, 21 (5), 1081-1085 (1993).
Signas et al., Journal of Virology, 53 (2), 672-678 (1985).
Silver et al., Virology, 165, 377-387 (1988).
Stewart et al., EMBO Journal, 12 (7), 2589-2599 (1993).
Wagner et al., Proc. Natl. Acad. Sci. USA, 89, 6099-6103 (1992).
Watkins et al., presented at Keystone Symposium on Molecular and Cellular Biology, Abst. No. 336 (Taos: NM, Feb. 22-28, 1996).
Watson et al., Journal of Virology, 69, 525-535 (1988).
Wickham et al., Cell, 73, 309-319 (1993).
Wickham et al., Gene Therapy, 2, 750-756 (1995).
Wickham et al., Journal of Cell Biology, 127 (1), 257-264 (1994).
Wickham et al., Journal of Virology, 70, 6831-6838 (1996).
Xia et al., Structure, 2, 1259-1270 (1994).

Affiliated with

Also associated with

Rating

Targeting adenovirus with use of constrained peptide motifs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeting adenovirus with use of constrained peptide motifs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeting adenovirus with use of constrained peptide motifs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1592979